The objective of this study is to evaluate clinical outcomes among levofloxacin, cefepime, and carbapenem used for ESBL-producing Enterobacteriaceae infections. Additional objectives include identifying risk factors that can help tailor antibiotic therapy.
Haidar et al., "Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections," Clinical Infectious Diseases, vol.
Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam, zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections).
In the data presented, a DDS-04 series compound cured infection in a translationally-relevant animal model of urinary tract infection, one of the major sites for Enterobacteriaceae infection. Therapeutic concentrations of the DDS-04 compound were also observed in other major sites in the animal model where life-threatening Enterobacteriaceae infections occur, including the lungs and the bloodstream.